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Background/aim: The clinical characteristics and treatment results of febrile neutropenia attacks that occurred in patients with
lymphoma and solid tumors were analyzed.
Materials and methods: A total of 50 patients with 94 high-risk attacks were evaluated for malignant diseases in this study.
Results: The fever etiology was determined as clinical (50%), microbiological (5.31%), clinical-microbiological (5.31%), or unknown
(39.3%). A few of the attacks (21.3%) were observed in lymphoma cases and 77.7% were observed in patients with solid tumors. Patients
who were in remission had 59.6% of the attacks, and 39.4% occurred in patients not in remission. Among the groups tested, 73%
(the imipenem/amikacin group) and 47.9% (the piperacillin-tazobactam/amikacin group) of patients were in remission. Glycopeptide
addition rates in these groups were 22.2% and 40.8% and antifungal addition rates were 8.8% and 18.3%, respectively.
Conclusion: Clinical progress was more problematic in patients who were not in remission during the attacks. This was due to the fact
that some patients had other factors that placed them in the high-risk group, as well as increased C reactive protein and procalcitonin
values on the first day. Therefore, it may not be accurate to associate the success achieved in the different treatment regimens with
antibiotics alone.
Key words: Childhood, febrile, high risk, neutropenia

1. Introduction
Neutropenia is a condition where the absolute neutrophil
count (ANC) is lower than 1500 cells/µL or is expected to
drop below 500 cells/µL within a 48-h time period. When
classifying the condition, 1000–1500 ANC/µL is accepted
as mild, 500–1000 ANC/µL is accepted as intermediary, and
less than 500 ANC/µL is accepted as severe neutropenia.
On the other hand, neutropenic fever is a condition where
the body temperature is greater than 38 °C for more than
1 h or is measured to be higher than 38 °C twice during
a 12-h period (1). The signs and occurrence of infection
in a neutropenic patient are also evaluated as febrile
neutropenia (FN), even if there is no fever (2).
In this study, clinical characteristics, treatment results
of the FN attacks occurring in our patients with lymphoma
and solid tumors factors treated due to FN, and factors
influencing clinical pursuit and treatment results were
compared with the literature.
* Correspondence: drdogankose@gmail.com

2. Materials and methods
2.1. Ethical declaration
Ethical approval of the study was granted by the scientific
research ethics board of our university.
2.2. Patients
In this study, 94 high-risk FN attacks that occurred in 50
pediatric patients were examined retrospectively. Patients
with lymphoma and solid tumors received chemotherapy
for malignant disease in the Pediatric Hematology and
Oncology Clinic between the years of 2011 and 2013.
2.3. Criteria for exclusion from the study
Patients with one of the following factors were excluded
from the study: leukemia, a neutrophil count and fever
that did not comply with the criteria described below,
the source of fever being thought to be noninfectious, the
patient being older than 18, the patient having had received
antibiotics during the last 10 days, and the administration
of glycopeptide (GP) at the beginning.
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2.4. Clinic and laboratory evaluation
When patients with FN were admitted to our clinic, their
histories were evaluated rapidly and physical examinations
were made. Afterwards, materials were taken for
complete blood, biochemical (glucose, urea, creatinine,
transaminase, electrolytes, lactate dehydrogenase, and
alkaline phosphatase), peripheral smear, C reactive
protein (CRP), procalcitonin (PCT), and complete urine
and culture tests (blood and from the other suspected
regions) and direct chest radiography. Body temperature
was measured and accepted as fever if the temperature was
greater than 38 °C at least once or measured to be greater
than 37.5 °C for longer than 1 h by an axillary method.
In addition, neutropenia was diagnosed when ANC levels
were less than 500 cells/mm3.
Patients were placed in the high-risk group (Group
1) if the ANC value was less than 100 cells/mL with
the expectation of it lasting more than 7 days, liver or
renal failure (aminotransferase levels >5 times normal
or creatinine clearance <30 mL/min, respectively),
hemodynamic instability, mucositis causing swallowing
malfunction, abdominal pain, nausea, vomiting, diarrhea,
newly beginning neurological and mental situation
changes, intravascular catheter infection, new pulmonary
infiltrations, hypoxemia and underlying chronic lung
illness, infant acute lymphoblastic leukemia, acute myeloid
leukemia, or being in the first 30 days following a stem cell
transplantation.
First, antibiotic dosages were administered within
approximately 1.5–2 h after the patients applied to the
hospital. On the following 3rd, 5th, and 7th days, complete
blood counts and peripheral smear tests were repeated. In
addition, CRP and PCT tests were repeated on the seventh
day. The etiology of the fever was classified as clinical,
microbiologic, clinical-microbiological infection, or fever
with unknown reasons.
2.5. Antibiotherapy
The selection of antibiotics that were administered was
completely random. A regime [imipenem/amikacin (IA)]
was applied for all patients between certain dates. Later,
another regime [piperacillin-tazobactam/amikacin (PA)]
was applied. Clinical treatment success was accepted if there
were no signs of fever for 5 days, no need for modification
of the treatment, loss of clinic and laboratory symptoms,
eradication of the developed bacteria, and nonrecurrence
of the infection in the first 7 days after cessation of the
treatment. On the other hand, failure was determined if
the patient died, had persistent bacteremia or new bacterial
production, and if there was any modification or addition
to the initial treatment. If there were indications that it
was necessary (1), or if fever persisted longer than 72 h,
then GP was added to the initial treatment (3). When fever
persisted until the end of the fifth day, thorax tomography
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was conducted and an antifungal (AF) was included in
the treatment (3). Among the medicines, imipenem was
administered as 15 mg/kg per dose (4 doses), piperacillintazobactam as 80 mg/kg per dose (4 doses), amikacin as
7.5 mg/kg per dose (2 doses), liposomal amphotericin B
as 4 mg/kg per dose (1 dose), voriconazole as 7 mg/kg per
dose (2 doses), and caspofungin as 70 mg/m2 per dose on
the first day and 50 mg/m2 per dose (1 dose) later.
2.6. Duration of the treatment
No modification was made in the initial treatment for
patients whose fever dropped during the first 3 days if there
was no growth in their cultures as well. Once the ANC was
greater than 500 µL, the treatment was continued for at
least 48 h. Clinical symptoms and patient recovery were
evaluated for the decision to terminate the treatment.
Treatment was continued for at least 4–5 days after the
patient’s ANC value increased above 500 cells/µL. If the
fever still did not drop GP and AF were added to the initial
treatment as long as there was no growth in the cultures.
The treatment was discontinued when there was clinical
improvement in patients (the ANC was determined as
under 500 cells/µL at the end of the 14th day).
2.7. Statistical analysis
Statistical analysis of the study was done using SPSS 16.
In group comparisons for parameters for which a normal
distribution approach could not be achieved, the Mann–
Whitney test was used as a nonparametric test.
For parameters for which a normal distribution approach
could be achieved, an independent t-test was used as a
parametric test. Categorical data were analyzed using a
crosstabs Fisher exact test. Correlation coefficients for some
related parameters were evaluated by the Spearman rank
correlations technique and some identifier characteristics
were evaluated by the aid of identifying statistical tests. P <
0.05 was accepted as statistically significant.
3. Results
The sex representation of our study was 46% boys and 54%
girls. Attacks occurred in 52.1% of the boys and 47.9%
of the girls. A few of the attacks (21.3%) were observed
in lymphoma cases and 77.7% were observed in patients
with solid tumors. There was no significant difference
determined in any of the parameters when values of these
groups were compared.
In 56.4% of all attacks, the number of risk factors
placing the patients in the high-risk group was greater
than 3. In this group, the number of days with fever and
AF starting rates were significantly higher in comparison
to the other group (Table 1).
Patients who were not in remission had 39.4% of the
attacks. In this group, initial creatinine (Cr) and CRP
values on the 1st and 7th days, PCT values on the 7th day,
and number of days with fever were significantly high.
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Table 1. Parameters found as significant when compared according to the number of risk factors patients had
(≤2 and ≥3).
NRF ≤2 (42.6%)

NRF ≥3 (56.4%)

Mean

Interval

Mean

Interval

P-value

DWF

2.2 ± 1.6

1.0–7.0

3.1 ± 2.1

1.0–7.0

0.020

AF given

5.0%

20.8%

AF not given

95.0%

79.2%

Parameter

0.027

AF: Antifungal, DWF: number of days with fever, NRF: number of risk factors.

In the same group, AF starting rates and the number of
factors placing the patients in the high-risk group were
significantly high (Table 2).
The reason for the fever was evaluated as clinical in
50% of the attacks, microbiological in 5.31%, and clinicalmicrobiological in 5.31%. The cause of the fever was not
able to be determined in 39.3% of the attacks (Table 3).
PCT values on the 1st and 7th days, number of days
with fever, and AF starting rates were significantly higher
in the group who had a CRP level of >100 mg/L on the first
day (Table 4).
In the group that had PCT values greater than 0.61 ng/
mL, the CRP values on the 1st and 7th days along with
the number of days with fever were significantly high.
On the first day, thrombocyte values were significantly
low. In addition, the AF starting rate and the number of
factors placing the patients in the high-risk group were
significantly increased in the same group (Table 5).

Patients who started with PA as an initial treatment
had significantly higher CRP values on the 1st and 7th
days, PCT values on the 7th day, and number of days with
fever when compared to the other group. A majority of the
patients in the IA group were in remission (73.3%), while
in the PA group this percentage was 47.9% (Table 6).
The number of total attacks for which IA was started was
45 (40% of total). Out of these, 22.2% were administered
GP initially and 4 of these 40% were started with AF. When
45 patients were evaluated, the AF starting rate was 8.8%
in this group. The number of total attacks for which PA
was started was 49. Out of these, 40.8% were administered
GP initially, and 45% started with AF. When a calculation
was made based on 49 patients, the AF starting rate in the
group receiving PA was 18.3%. Of all attacks, 13.8% were
given AF treatment. CR and CRP values on the 1st and
7th days, PCT values on the 7th day, and number of days
with fever and neutropenia in patients receiving AF were

Table 2. Parameters found as significant when attacks of those whose malignant diseases were in remission or not in remission were
compared.
Those in remission (59.6%)

Those not in remission (39.4%)

Mean

Interval

Mean

Interval

Cr (mg/dL)

0.5 ± 0.2

0.3–1.4

0.6 ± 0.2

0.4–1.9

0.045

Day 1 CRP (mg/L)

46.3 ± 45.7

2.0–168

82.6 ± 57.8

4.0–204.0

0.001

Day CRP 7 (mg/L)

19.7 ± 27.6

2.0–142

59.2 ± 67.3

2.0–211.0

<0.001

Day 1 PCT (ng/mL)

0.2 ± 0.4

0.01–2.8

2.3 ± 4.1

0.05–16.2

0.001

DWF

2.3 ± 1.5

1.0–7.0

3.3 ± 2.2

1.0–7.0

0.018

NRF (≤2)

53.6%

27.0%

NRF (≥3)

46.4%

73.0%

0.010

AF given

7.1%

24.3%

0.022

AF not given

92.9%

75.7%

Parameter

P-value

AF: Antifungal, Cr: creatinine, CRP: C reactive protein, DWF: number of days with fever, NRF: number of risk factors, PCT: procalcitonin.
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Table 3. Fever etiology, diagnostic method, rates, produced effects, and production locations in all patient groups.
Diagnosis method of infection
Clinical

Microbiological

Clinical-microbiological

FUO

n = 47 (50%)

n = 5 (5.31%)

n = 5 (5.31%)

n = 37(39.3%)

Infection area

The field produced

Agent produced

Infection area

The field produced

Agent produced

URT: 39

Blood

Str. oralis

GIS

Blood

SE

GIS: 6

Urine

EC

URT

Blood

Klebsiella

LRT: 2

Urine

EC

URT

Blood

SE

Urine

EC

URT

Blood

SE

Urine

Enterococci

URT

Urine

EC

EC: Escherichia coli, FUO: fever of unknown origin, GIS: gastrointestinal system, LRT: lower respiratory tract, SE: Staphylococcus epidermidis,
URT: upper respiratory tract.

Table 4. Parameters found as significant when patients were compared according to day 1 CRP.
CRP = 5.1–100 (72.9%)

CRP > 100 (27.1%)

Parameter

Mean

Interval

Mean

Interval

Day 1 PCT (ng/mL)

1.1 ± 3.8

0.07–28.1

5.5 ± 16

0.1–75.0

0.046

Day 1 PCT (ng/mL)

0.6 ± 2.3

0.04–16.2

2.5 ± 3

0.05–12.1

0.015

DWF

2.4 ± 1.8

1.0–7.0

3.7 ± 2

1.0–7.0

0.008

AF given

9.7%

30.4%

AF not given

90.3%

69.6%

P-value

0.025

AF: Antifungal, CRP: C reactive protein, DWF: number of days with fever, PCT: procalcitonin.
Table 5. Parameters found as significant when patients are compared according to day 1 PCT.
PCT = 0.11–0.60 (66.3%)

PCT ≥ 0.61 (33.7%)

Parameter

Mean

Interval

Mean

Interval

Day 1 CRP (mg/L)

42.3 ± 43

2.0–163.0

101.3 ± 48

21.0–204.0

<0.001

Day 7 CRP (mg/L)

18.4 ± 30

2.0–192.0

68.6 ± 67

2.0–211.0

<0.001

Day 1 PLT

78.9 ± 57

3000–233,000

54.3 ± 47

7000–195,000

0.043

DWF

2.3 ± 1

1.0–7.0

3.8 ± 2

1.0–7.0

0.003

NRF (≤2)

49.1%

27.6%

NRF (≥3)

50.9%

72.4%

AF given

7.0%

31.0%

AF not given

93.0%

69.0%

P-value

0.045
0.005

AF: Antifungal, CRP: C reactive protein, DWF: number of days with fever, NRF: number of risk factors, PCT: procalcitonin, PLT:
platelets.
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Table 6. Parameters with significant differences when the values of the groups treated with IA and PA were compared.

Parameter

IA (47.9%)

PA (51.1%)

P-value

Mean

Interval

Mean

Interval

Day 1 CRP (mg/L)

49.3 ± 47.5

2.0 - 204.0

71.8 ± 57

4.0–175.0

0.044

Day 7 CRP (mg/L)

23.1 ± 41.4

2.0 - 211.0

46.2 ± 56

2.0–201.0

0.034

Day 7 PCT (ng/mL)

0.3 ± 0.5

0.01–2.8

1.8 ± 3

0.04–16.2

0.011

DWF

2.2 ± 1.8

1.0–7.0

3.2 ± 2

1.0–7.0

0.012

Those in remission

73.3%

47.9%

Those not in remission

26.7%

52.1%

0.011

CRP: C reactive protein, DWF: number of days with fever, IA: imipenem/amikacin, PA: piperacillin-tazobactam/amikacin, PCT:
procalcitonin.

significantly higher in comparison to the group that did
not receive AF (Table 7).
4. Discussion
It was previously reported that FN was found most
frequently in hematological malignancies (4),
osteosarcoma, and Ewing’s sarcoma (ES) (5). In our
study, attacks were determined most frequently in nonHodgkin lymphoma, ES, and rhabdomyosarcoma,
respectively. When the number of attacks per patient was
evaluated, the ranking changed to rhabdomyosarcoma,
ES, and neuroblastoma. When the values of the patients
with lymphoma and other solid tumors were compared,
there was no significant difference determined in any of
the parameters. The situation and ranking differences
observed in the studies indicate that malignancy type is
not a determinant for FN on its own.
The patients were divided into 2 risk groups: high
and low, based on the evaluations (1). In our study, it
was determined that the number of days with fever

and, therefore, the AF starting empirical rate increased
significantly as the number of factors placing the patients
in the high-risk group increased. Because of this, we
propose that the risk factor number may give us ideas
about the clinical course that may be encountered and may
guide the selection of initial antibiotic.
Patients whose malignant diseases were not in
remission were placed in the high-risk group according to
their treatment guides (1). In our study, it was observed
that the CRP value on the 1st day, number of days with
fever, and AF onset rates were higher in the patients
who were in nonremission for malignant disease. This
situation was probably caused by severe myelosuppression
originating from the increase in the chemotherapeutic
medicine load, resulting from chemotherapy protocol
extension or changes to new protocols. Furthermore,
the fact that a difference occurred on the 7th day, when
there was no difference between the 1st day PCT values
of both groups, made us think that the patients who
were in remission reached lower PCT values on the 7th

Table 7. Parameters estimated to be significantly different when the values of the patient groups receiving AF and not receiving AF were
compared.
AF given (13.8%)

AF not given (85.1%)

Parameter

Mean

Interval

Mean

Interval

P-value

Day 1 CRP (mg/L)

105.1 ± 49

18.0–175.0

53.3 ± 50

2.0–204.0

0.001

Day 7 CRP (mg/L)

112.5 ± 64

14.0–201.0

22.3 ± 34

2.0–211.0

<0.001

Day 7 PCT (ng/mL)

4.2 ± 5

0.2–16.2

0.5 ± 1

0.01–9.4

<0.001

DWF

6.5 ± 0

1.0–7.0

2.1 ± 1

1.0–7.0

<0.001

Neutropenic days

6.4 ± 0

4.0–7.0

5.0 ± 1

2.0–7.0

0.001

AF: Antifungal, CRP: C reactive protein, DWF: number of days with fever, PCT: procalcitonin.
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day and their responses to the treatment were better.
In approximately 1/3 of all neutropenic attacks that
developed after chemotherapy, fever occurred (6).
Infection was not the root cause for approximately 31%
of them (7). In approximately 50% of all the attacks, the
infection was documented as microbiological and clinical
(8). In our study, infection was identified as clinical in
50% of the attacks, microbiological in 5.31%, and clinicalmicrobiological in 5.31%. In 39.3% of attacks, the fever was
accepted to be of unknown origin. Infections identified in
FN (apart from blood) were reported as lung, skin and
soft tissue, urinary system, sinus and oropharynx, skeletal
system, enteric track, and meninx (9). In the present
study, 52 attacks were determined as clinically infectious.
Infection regions were the upper respiratory tract,
gastrointestinal system, and lower respiratory track when
ranked according to frequency. The number of attacks
shown as microbiological was 10, and 5 of these 10 cases
were of urine origin, while the rest were of blood origin.
Although gram-negative bacteria were the most
frequent factors (10), increased usage of antimicrobial
agents and venous catheters have contributed to an
increase in gram-positive factors. It was reported that
46% of bacteremia attacks were gram-positive, 42%
were gram-negative, and 12% were polymicrobial (10).
However, gram-negative dominance was reported in
Israel, Singapore (11), and Turkey (12), as well. The most
frequent gram-positive pathogens are coagulase-negative
Staphylococcus, Streptococci viridans, and Staphylococcus
aureus. In bacteremic episodes caused by aerobic
gram-negative bacilli, Escherichia coli was the factor in
approximately 1/3 to 1/2 of the cases, as well as other
contributors (including Klebsiella spp., Pseudomonas spp.,
Acinetobacter spp., and Enterobacter spp.) (13). In our
study, 60% of the producible factors were gram-negative.
Gram-negative pathogens were Escherichia coli (66.6%),
Klebsiella (16.6%), and Enterococcus (16.6%). Grampositive pathogens were Staphylococcus epidermidis (75%)
and Streptococcus oralis (25%).
CRP elevation sensitivity in infection was 56%–100%.
However, the 24–48 h required to see any significant
increase and the interaction between the primary disorder
and CRP are disadvantages for this marker (14). On the
other hand, PCT increases in sepsis, multiple organ failure,
and bacterial, fungal, and parasitic infections and remains
extremely low in neoplastic disorders (15). Furthermore,
its level is comparative to the degree of microbial invasion,
and it increases rapidly in comparison to CRP (16).
In our investigation, the group with higher CRP values
on the first day had PCT values on the 1st and 7th days that
were significantly higher in comparison to the other group.
The group with higher PCT values on the 1st day had
CRP values on the 1st and 7th days that were significantly
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higher in comparison to the other group. This illustrates
that both parameters progress in parallel. They increase as
an answer to infection and drop as an answer to treatment.
In the groups with higher CRP and PCT values on the
1st day, the higher number of days with fever and higher
AF administration rates illustrate that both parameters
increase in parallel to the intensity of the infection and that
1st day values can give an idea about the expected clinical
progress.
In our study, the initial CRP values were normal in
7.44% of all the attacks, and there was no need for the
addition of GP in any of them. The lowest CRP value
for which GP was added was 18.5 mg/L, and the lowest
CRP value for which AF was added was 37.4 mg/L. On
the other hand, the initial PCT values were normal in
5.31% of 94 attacks, and the need for modification arouse
only in 1 of them. In addition, the lowest PCT value for
which AF was added was 0.29 ng/mL and the lowest PCT
value for which AF was added was 0.30 ng/mL. The initial
false negative values were close. Since there was a GP
requirement in a patient with a normal PCT value, and
the lowest PCT values for which GP and AF were added
were close to each other, it was thought that CRP could
be a little more advantageous in comparison to PCT in
the current manifestation and for illustrating expected
clinical progress. However, in the group with higher day
1 PCT values, the fact that the number of factors placing
the patients in a high-risk group was greater implies an
advantage on behalf of PCT as well.
In patients with neutropenia and bacteremia, the death
rate was 40% during the first 48 h following identification
of the fever (17), and the mortality diminished due to
empirical antibiotic treatment that was started immediately
(18).
Although gram-positive pathogens are more frequent,
gram-negatives are more vital because of their virulence and
their relationship with sepsis (19). Therefore, the Infectious
Diseases Society of America proposed a combination of
an aminoglycoside and an antipseudomonal beta-lactam
in the initial empirical treatment for high-risk patients (3).
The beta-lactam agent could be a 3rd or 4th generation
cephalosporin, a beta-lactam with beta-lactamase
inhibitor, or a carbapenem. On the other hand, if there are
data available about sensitivity, the aminoglycoside should
be gentamicin, tobramycin, or netilmicin. If sufficient data
are lacking, amikacin should be used because it is the least
resistance-developing member (20).
Piperacillin is a broad spectrum ureidopenicillin.
Tazobactam is a beta-lactamase inhibitor and an
effective agent against many gram-positive and gramnegative pathogens, including anaerobic pathogens and
Pseudomonas aeruginosa (21). Carbapenems have excellent
activity against both gram-negative and gram-positive

KÖSE et al. / Turk J Med Sci
bacteria, including beta-lactamase-producing gramnegatives (22). Aminoglycosides used in combination
may cause an increase in nephrotoxicity and ototoxicity,
especially in patients receiving chemotherapy. However,
the combination has advantages, such as a synergic effect
and the prevention of resistance development (23).
Studies comparing piperacillin-tazobactam and
carbapenems (±amikacin) (24), piperacillin-tazobactam
and imipenem (12), piperacillin-tazobactam + amikacin,
and meropenem + amikacin (25) have reported equal levels
of efficiency in the initial treatment. On the other hand,
there are reports indicating that they reduce mortality in
comparison to other beta-lactams containing carbapenems
or piperacillin-tazobactam (26). In addition, more
modification is required in patients receiving piperacillintazobactam in comparison to those who receive carbapenem
(24). In another investigation, success rates in the initial
treatment were reported to be 31% for cases treated with
piperacillin-tazobactam (±amikacin) and 42% (27) for
those treated with carbapenems. In our study, the success
rate with the initial treatment in the group that started
with PA was 59.1%, and it was 77.8% in the group that
started with IA. However, this could be the result of lower
remission rates (47.9%) in the PA group in comparison to
the IA group (73.3%). The significantly higher day 1 CRP
values in PA-started attacks in comparison to the IA-started
group supports this notion, as well.
Modification rates with GPs have risen from 5%–8% up
to 20% during recent years in parallel with central venous

catheter utilization. AF addition rate is 3%–10% (28). In
our study, GP addition rate was 31.9% and AF addition
rate was 13.8%.
Mortality has dropped to 0.4%–1% in FN, owing to
empiric antibiotic treatment and improvement in care
opportunities (29). Only one person died among the
patients included in our investigation. This patient was a
16-year-old male with ES diagnostics. PA was started as
the initial treatment; however, GP and AF were also added
to the treatment regime later on. This patient was not in
remission, and the infection source determined in his
last attack was the upper respiratory tract. However, the
manifestation developed towards sepsis and the patient
was lost. Therefore, the mortality rate in our investigation
was determined to be 1.06%.
In this study, clinical progress was observed as more
problematic in patients who were not in remission
during attacks. This resulted in the placement of patients
with a higher number of factors in the high-risk group
with high day 1 CRP and PCT values. Thus, it may be
beneficial to consider these factors in the selection of the
initial antibiotic regime. On the other hand, it may not
be accurate to attribute the success attained by various
treatment regimens only to antibiotics. It is possible
that the response gained from the treatment may be
influenced by many factors, including the remission state
of the patient, number of risk factors, infection type, total
dosage of the administered chemotherapeutics, and their
myelosuppressive effects.
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